Development of Multistaged Nanoparticles As Cancer Vaccines : International School of Nanomedicine
Flavia Fontana,Mohammad‐Ali Shahbazi,Dongfei Liu,Hongbo Zhang,Ermei Mäkilä,Jarno Salonen,Jouni Hirvonen,Hélder A. Santos
2017-01-01
Abstract:Nanoparticles present suitable characteristics for use as vaccine adjuvants due to their size, the natural target in the lymph nodes, the possibility to co-deliver antigens and adjuvants, as well as the intrinsic adjuvant effect shown by some nanomaterials.1-3 We propose a multistaged cancer nanovaccine made of an adjuvant nanoparticle and an innovative source of neoantigens, vesicles derived from the membrane of cancer cells, coating the nanoparticles. The adjuvant nanoparticles were prepared by nanoprecipitation in a glass capillary microfluidic device from porous silicon nanoparticles and acetalated dextran. The nanovectors were highly cytocompatible for peripheral blood monocytes (PBMC) isolated from healthy donors and immortalized cell lines. Moreover, they induced the expression of co-stimulatory signals (CD80 and 86), the secretion of pro-inflammatory cytokines (IFN-γ), and inhibited, when incubated with the activated PBMCs, the proliferation of cancer cells of the same cell line used as source of membranes. Overall, the developed system showed excellent properties as adjuvant in vitro, with promising future applications in personalized treatments for cancer immunotherapy.References1. D. J. Irvine, M. C. Hanson, K. Rakhra and T. Tokatlian, Chem rev, 2015, 115, 11109-11146.2. F. Fontana, D. Liu, J. Hirvonen and H. A. Santos, Wiley Interdiscip Rev Nanomed Nanobiotechnol, 2016, DOI: 10.1002/wnan.1421.3. K. T. Gause, A. K. Wheatley, J. Cui, Y. Yan, S. J. Kent and F. Caruso, ACS Nano, 2017, 11, 54-68.